Allergic Rhinitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for allergic rhinitis. 262 active patents protecting 11 drugs from 8+ originators. First major cliff: 2027. Daily refresh.

11
Approved drugs
262
Active US patents
64/100
Avg vulnerability
$8.8B
Annual revenue covered

Originators in Allergic Rhinitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Haleon Us Holdings 41 patents AstraZeneca K.K. 37 patents Generic (originally Schering) 36 patents Merck & Co. 22 patents Covis 4 patents Bayer 3 patents Padagis Us 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating allergic rhinitis. Each bar = one year. Y-axis scaled to peak year (41 patents).

9
26
16
27
10
28
9
29
30
30
41
31
8
32
4
33
31
34
18
35
13
36
3
37
3
38
25
39
28
40
8
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Arnuity Ellipta
FLUTICASONE FUROATE
 Haleon Us Holdings 41 61 $3.1B 2027-06-14
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Omnaris
CICLESONIDE
 Covis 4 80 — 2028-02-01
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03
Mucinex
guaifenesin
 Generic (multiple manufacturers) 3 62 — 2035-11-13
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
 Bayer 3 60 — 2027-02-28
Verdeso
DESONIDE
 Padagis Us 1 80 $2.8B 2027-08-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9119863 Pulmicort Respules method of use 93 2026-11-09
8497258 Pulmicort Respules method of use 93 2026-11-09
8975243 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8511304 Arnuity Ellipta method of use 83 2027-06-14
11116721 Arnuity Ellipta method of use 83 2029-02-26
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
7488827 Arnuity Ellipta composition of matter 17 2027-12-18
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10406332 Elocon formulation 25 2034-03-13
10799642 Decadron formulation 31 2032-05-11
8763222 Elocon formulation 31 2032-02-08
8409606 Decadron formulation 31 2030-05-14
11679210 Elocon formulation 33 2038-09-03

Related